Marcus Lee, MD
Family Medicine · Tullahoma, TNNPI 1457364077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,070 and has fallen 61.3% since, to $414 in 2025.
Across 132 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$430
- Johnson & Johnson$156
- AstraZeneca$148
- Bayer$134
- Takeda Pharmaceuticals U.S.A., Inc.$109
- Amgen$95
- plus $783 from 20 others
Across 509 payments — averaging $2938.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.1M
- AbbVie$237K
- Novo Nordisk AS$121K
- GSK$57K
- Chiesi USA, Inc.$11K
- AstraZeneca$5K
What the payments were for
- Food & beverage$1,75595%
- Education$814%
- Gifts$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $430 |
| Johnson & Johnson | 15 | $156 |
| AstraZeneca | 11 | $148 |
| Bayer | 7 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $109 |
| Amgen | 6 | $95 |
| AbbVie | 4 | $74 |
| Boehringer Ingelheim | 4 | $74 |
| Exact Sciences | 4 | $70 |
| Merck | 4 | $65 |
| Pfizer | 8 | $61 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Boston Scientific | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Lilly USA, LLC | 3 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| GSK | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $27 |
| Novartis | 2 | $24 |
| Valeritas, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$1,856 in reported general payments places this provider in the 65th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 196 | $215,788 |
| MounjaroTirzepatide | 143 | $152,411 |
| JardianceEmpagliflozin | 90 | $106,899 |
| EliquisApixaban | 71 | $65,287 |
| FarxigaDapagliflozin Propanediol | 36 | $45,433 |
| JanuviaSitagliptin Phosphate | 45 | $44,810 |
| TrulicityDulaglutide | 33 | $40,184 |
| XareltoRivaroxaban | 31 | $34,649 |
| RybelsusSemaglutide | 25 | $31,652 |
| LinzessLinaclotide | 34 | $30,358 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $29,840 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $25,835 |
| MyrbetriqMirabegron | 28 | $24,433 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $24,053 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $17,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $430 | $247,440221 claims |
| Lilly USA, LLCMounjaro, Trulicity | $44 | $192,594176 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $74 | $132,288130 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $148 | $75,27379 claims |
| PfizerEliquis | $61 | $65,28771 claims |
| MerckJanuvia | $65 | $44,81045 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $30 | $41,93660 claims |
| Johnson & JohnsonXarelto | $156 | $34,64931 claims |
| AbbVieLinzess | $74 | $30,35834 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $58 | $21,61636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Tullahoma
- John AndersonTullahoma$23K
- John PatsimasTullahoma$14K
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.